SFRP4 and ovarian carcinoma: Wnt signaling can be competitively inhibited by secreted frizzled-related protein 4 (SFRP4), the loss of which has been associated with poor outcomes in ovarian cancer patients [53] and decreased responsiveness of ovarian cancer cells to cisplatin in vitro [54].